|
|
 Previous Article | Table of Contents | Next Article 
BCL-6 Protein Expression in Human Peripheral T-Cell Neoplasms Is Restricted to CD30+ Anaplastic Large-Cell Lymphomas
Antonino Carbone,
Annunziata Gloghini,
Gianluca Gaidano,
Riccardo Dalla-Favera, and
Brunangelo Falini
From the Division of Pathology, Centro di Riferimento Oncologico, Istituto Nazionale di Ricovero e Cura a Carattere Scientifico, Aviano, Italy; the Division of Internal Medicine, Department of Medical Sciences, University of Torino at Novara, Novara, Italy; the Division of Oncology, Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, NY; and the Institute of Hematology, University of Perugia, Perugia, Italy.
The expression pattern of the BCL-6 transcription factor has been assessed in normal and neoplastic B-cell populations and in Hodgkin's disease. However, little is known about BCL-6 expression and its biological significance in T-cell neoplasms. In this study, a series of 59 lymphoma samples, including 27 CD30+ anaplastic large-cell lymphomas (ALCLs), 24 other peripheral T-cell neoplasms, and 8 T-cell lymphoblastic lymphomas (T-LBLs), as well as a panel of t(2; 5)-positive lymphoma-derived human cell lines, were evaluated for BCL-6 protein expression by immunohistochemistry on frozen sections and cell smears. To define the relationship between BCL-6 protein and CD30 antigen in CD30+ ALCLs and in non-neoplastic lymph nodes, serial section immunohistochemistry and two-color staining were used in selected CD30+ ALCLs as well as in reactive lymph nodes with non-neoplastic T-cell proliferations. BCL-6 protein was expressed in 12 of 27 (45%) CD30+ ALCL cases, irrespective of their antigenic phenotypes (T-cell or null-cell type), and in the t(2; 5)-positive cell lines. In contrast, the remaining 24 peripheral T-cell neoplasms as well as the 8 T-LBLs were considered negative for BCL-6 expression. Coexpression of CD30 and BCL-6, as detected in CD30+ ALCLs, was also found in a subset of non-neoplastic lymphoid elements, namely the large lymphoid cells scattered in the interfollicular areas of reactive lymph nodes. These findings suggest that CD30+ ALCLs may represent the neoplastic transformation of extrafollicular CD30+ cells and that BCL-6 may provide an additional marker for characterizing CD30+ ALCLs.
Blood, Vol. 90 No. 6 (September 15), 1997:
pp. 2445-2450
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Lamant, A. d. Reynies, M.-M. Duplantier, D. S. Rickman, F. Sabourdy, S. Giuriato, L. Brugieres, P. Gaulard, E. Espinos, and G. Delsol
Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes
Blood,
March 1, 2007;
109(5):
2156 - 2164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Falini and D. Y. Mason
Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry
Blood,
January 15, 2002;
99(2):
409 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hyjek, A. Chadburn, Y. F. Liu, E. Cesarman, and D. M. Knowles
BCL-6 protein is expressed in precursor T-cell lymphoblastic lymphoma and in prenatal and postnatal thymus
Blood,
January 1, 2001;
97(1):
270 - 276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Dent, T. M. Doherty, W. E. Paul, A. Sher, and L. M. Staudt
BCL-6-Deficient Mice Reveal an IL-4-Independent, STAT6-Dependent Pathway That Controls Susceptibility to Infection by Leishmania major
J. Immunol.,
August 15, 1999;
163(4):
2098 - 2103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Dent, J. Hu-Li, W. E. Paul, and L. M. Staudt
T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6
PNAS,
November 10, 1998;
95(23):
13823 - 13828.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Nicolaides, S. Dimou, and N. Pavlidis
Prognostic Factors in Aggressive Non-Hodgkin's Lymphomas
Oncologist,
June 1, 1998;
3(3):
189 - 197.
[Abstract]
[Full Text]
|
|
|
|
|
